Nautilus Biotechnology, Inc.
$2.96
▼
-1.49%
2026-04-21 08:20:01
www.nautilus.bio
NCM: NAUT
Explore Nautilus Biotechnology, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$383.49 M
Current Price
$2.96
52W High / Low
$4.31 / $0.62
Stock P/E
—
Book Value
$1.24
Dividend Yield
—
ROCE
-36.49%
ROE
-32.27%
Face Value
—
EPS
$-0.47
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
130
Beta
0.99
Debt / Equity
19.12
Current Ratio
13.32
Quick Ratio
13.33
Forward P/E
-3.99
Price / Sales
—
Enterprise Value
$299.98 M
EV / EBITDA
-4.61
EV / Revenue
—
Rating
None
Target Price
$4
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | AIM ImmunoTech Inc. | $0.49 | — | $3.99 M | — | 2638.91% | 251.38% | $19.74 / $0.51 | $-3.19 |
| 2. | Tectonic Therapeutic, Inc. | $28.76 | — | $554.1 M | — | -33.43% | -37.82% | $36.03 / $14.39 | $13.41 |
| 3. | Karyopharm Therapeutics Inc. | $8.94 | — | $193.06 M | — | -554.58% | 81.86% | $10.99 / $3.65 | $-16 |
| 4. | Ligand Pharmaceuticals Incorporated | $231.78 | 36.85 | $4.59 B | — | 3.1% | 13.47% | $238.31 / $98.89 | $51.44 |
| 5. | Xenon Pharmaceuticals Inc. | $57.09 | — | $5.48 B | — | -63.09% | -51.76% | $63.95 / $28.19 | $7.27 |
| 6. | AN2 Therapeutics, Inc. | $3.62 | — | $129.78 M | — | -71.59% | -52.14% | $6.91 / $1 | $1.94 |
| 7. | Alpha Tau Medical Ltd. | $8.11 | — | $706.72 M | — | -44.45% | -61% | $8.6 / $2.5 | $0.88 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -15.42 M | -15.47 M | -17.1 M | -18.84 M | -19.98 M | — |
| Net Profit | -13.78 M | -13.57 M | -15.03 M | -16.61 M | -17.59 M | — |
| EPS in Rs | -0.11 | -0.11 | -0.12 | -0.13 | -0.14 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -66.84 M | -81.48 M | -76.15 M | -63.62 M |
| Net Profit | -59 M | -70.78 M | -63.67 M | -57.92 M |
| EPS in Rs | -0.47 | -0.56 | -0.5 | -0.46 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 191.11 M | 242.74 M | 305.56 M | 350.05 M |
| Total Liabilities | 34.14 M | 34.01 M | 40.21 M | 35.13 M |
| Equity | 156.97 M | 208.73 M | 265.35 M | 314.92 M |
| Current Assets | 105.96 M | 132.83 M | 176.84 M | 187.21 M |
| Current Liabilities | 7.95 M | 7.63 M | 9.12 M | 6.79 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -50.7 M | -59.15 M | -51.71 M | -45.81 M |
| Investing CF | 35.22 M | 66.25 M | -43.73 M | -25.74 M |
| Financing CF | 0.21 M | 1.14 M | 0.37 M | 0.56 M |
| Free CF | -51.97 M | -61.27 M | -54.15 M | -48.13 M |
| Capex | -1.28 M | -2.12 M | -2.44 M | -2.32 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -11.16% | -9.93% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.